REPLIGEN CORP (RGEN) Stock Fundamental Analysis
NASDAQ:RGEN - Nasdaq - US7599161095 - Common Stock - Currency: USD
Overall RGEN gets a fundamental rating of 4 out of 10. We evaluated RGEN against 55 industry peers in the Life Sciences Tools & Services industry. While RGEN has a great health rating, there are worries on its profitability. While showing a medium growth rate, RGEN is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
RGEN had positive earnings in the past year.
In the past year RGEN had a positive cash flow from operations.
Of the past 5 years RGEN 4 years were profitable.
RGEN had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
RGEN has a Return On Assets of -0.53%. This is in the better half of the industry: RGEN outperforms 65.45% of its industry peers.
Looking at the Return On Equity, with a value of -0.75%, RGEN is in the better half of the industry, outperforming 67.27% of the companies in the same industry.
With a Return On Invested Capital value of 0.41%, RGEN perfoms like the industry average, outperforming 60.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.53% | ||
| ROE | -0.75% | ||
| ROIC | 0.41% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Operating Margin of RGEN (2.29%) is comparable to the rest of the industry.
RGEN has a Gross Margin (50.28%) which is comparable to the rest of the industry.
RGEN's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.29% | ||
| PM (TTM) | N/A | ||
| GM | 50.28% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.48%
GM growth 5Y-4.99%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so RGEN is destroying value.
There is no outstanding debt for RGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 6.96 indicates that RGEN is not in any danger for bankruptcy at the moment.
RGEN has a Altman-Z score of 6.96. This is amongst the best in the industry. RGEN outperforms 89.09% of its industry peers.
The Debt to FCF ratio of RGEN is 3.97, which is a good value as it means it would take RGEN, 3.97 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of RGEN (3.97) is better than 76.36% of its industry peers.
RGEN has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.26, RGEN perfoms like the industry average, outperforming 56.36% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 3.97 | ||
| Altman-Z | 6.96 |
ROIC/WACC0.04
WACC10.31%
2.3 Liquidity
A Current Ratio of 10.44 indicates that RGEN has no problem at all paying its short term obligations.
RGEN's Current ratio of 10.44 is amongst the best of the industry. RGEN outperforms 92.73% of its industry peers.
RGEN has a Quick Ratio of 8.76. This indicates that RGEN is financially healthy and has no problem in meeting its short term obligations.
RGEN's Quick ratio of 8.76 is amongst the best of the industry. RGEN outperforms 90.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.44 | ||
| Quick Ratio | 8.76 |
3. Growth
3.1 Past
The earnings per share for RGEN have decreased strongly by -14.45% in the last year.
The Earnings Per Share has been growing slightly by 7.11% on average over the past years.
The Revenue has grown by 23.00% in the past year. This is a very strong growth!
The Revenue has been growing by 18.62% on average over the past years. This is quite good.
EPS 1Y (TTM)-14.45%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%33.33%
Revenue 1Y (TTM)23%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%7.58%
3.2 Future
RGEN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.43% yearly.
The Revenue is expected to grow by 15.90% on average over the next years. This is quite good.
EPS Next Y17.62%
EPS Next 2Y22.94%
EPS Next 3Y23.77%
EPS Next 5Y23.43%
Revenue Next Year10.14%
Revenue Next 2Y12.64%
Revenue Next 3Y13.75%
Revenue Next 5Y15.9%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 98.13, the valuation of RGEN can be described as expensive.
The rest of the industry has a similar Price/Earnings ratio as RGEN.
The average S&P500 Price/Earnings ratio is at 28.92. RGEN is valued rather expensively when compared to this.
With a Price/Forward Earnings ratio of 83.43, RGEN can be considered very expensive at the moment.
The rest of the industry has a similar Price/Forward Earnings ratio as RGEN.
RGEN is valuated expensively when we compare the Price/Forward Earnings ratio to 21.65, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 98.13 | ||
| Fwd PE | 83.43 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as RGEN.
RGEN's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 62.17 | ||
| EV/EBITDA | 91.63 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates RGEN does not grow enough to justify the current Price/Earnings ratio.
RGEN's earnings are expected to grow with 23.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)5.57
PEG (5Y)13.81
EPS Next 2Y22.94%
EPS Next 3Y23.77%
5. Dividend
5.1 Amount
RGEN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
145.23
+3.83 (+2.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners103.1%
Inst Owner Change0.32%
Ins Owners0.5%
Ins Owner Change3.03%
Market Cap8.16B
Analysts78.4
Price Target193.09 (32.95%)
Short Float %6.56%
Short Ratio5.43
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.55%
Min EPS beat(2)-0.8%
Max EPS beat(2)25.89%
EPS beat(4)1
Avg EPS beat(4)3.87%
Min EPS beat(4)-9%
Max EPS beat(4)25.89%
EPS beat(8)5
Avg EPS beat(8)10.39%
EPS beat(12)9
Avg EPS beat(12)13.86%
EPS beat(16)13
Avg EPS beat(16)22.42%
Revenue beat(2)0
Avg Revenue beat(2)-1.46%
Min Revenue beat(2)-1.99%
Max Revenue beat(2)-0.93%
Revenue beat(4)0
Avg Revenue beat(4)-1.45%
Min Revenue beat(4)-1.99%
Max Revenue beat(4)-0.93%
Revenue beat(8)0
Avg Revenue beat(8)-1.92%
Revenue beat(12)4
Avg Revenue beat(12)0.49%
Revenue beat(16)8
Avg Revenue beat(16)3.52%
PT rev (1m)-2.6%
PT rev (3m)-1.72%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.97%
EPS NY rev (1m)-0.99%
EPS NY rev (3m)-2.4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.05%
Revenue NY rev (1m)0.24%
Revenue NY rev (3m)0.25%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 98.13 | ||
| Fwd PE | 83.43 | ||
| P/S | 10.54 | ||
| P/FCF | 62.17 | ||
| P/OCF | 49.38 | ||
| P/B | 4.05 | ||
| P/tB | 12.59 | ||
| EV/EBITDA | 91.63 |
EPS(TTM)1.48
EY1.02%
EPS(NY)1.74
Fwd EY1.2%
FCF(TTM)2.34
FCFY1.61%
OCF(TTM)2.94
OCFY2.03%
SpS13.78
BVpS35.9
TBVpS11.54
PEG (NY)5.57
PEG (5Y)13.81
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.53% | ||
| ROE | -0.75% | ||
| ROCE | 0.65% | ||
| ROIC | 0.41% | ||
| ROICexc | 0.57% | ||
| ROICexgc | 1.95% | ||
| OM | 2.29% | ||
| PM (TTM) | N/A | ||
| GM | 50.28% | ||
| FCFM | 16.96% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.48%
GM growth 5Y-4.99%
F-Score5
Asset Turnover0.27
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 3.97 | ||
| Debt/EBITDA | 6.05 | ||
| Cap/Depr | 49.64% | ||
| Cap/Sales | 4.39% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 191.74% | ||
| Profit Quality | N/A | ||
| Current Ratio | 10.44 | ||
| Quick Ratio | 8.76 | ||
| Altman-Z | 6.96 |
F-Score5
WACC10.31%
ROIC/WACC0.04
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.45%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%33.33%
EPS Next Y17.62%
EPS Next 2Y22.94%
EPS Next 3Y23.77%
EPS Next 5Y23.43%
Revenue 1Y (TTM)23%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%7.58%
Revenue Next Year10.14%
Revenue Next 2Y12.64%
Revenue Next 3Y13.75%
Revenue Next 5Y15.9%
EBIT growth 1Y-68.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year67.28%
EBIT Next 3Y40.47%
EBIT Next 5Y37.38%
FCF growth 1Y34.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y12.56%
OCF growth 3YN/A
OCF growth 5YN/A